Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions | springermedicine.com

Springer Medicine

Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2007

Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions

Authors: Dagmar Hartung, Michael Schäfers, Shinichiro Fujimoto, Bodo Levkau, Navneet Narula, Klaus Kopka, Renu Virmani, Chris Reutelingsperger, Leo Hofstra, Frank D. Kolodgie, Artiom Petrov, Jagat Narula

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2007

Login to get access

Abstract

Introduction

Inflammation plays an important role in vulnerability of atherosclerotic plaques to rupture and hence acute coronary events. The monocyte–macrophage infiltration in plaques leads to upregulation of cytokines and metalloproteinase enzymes.

Matrix metalloproteinases result in matrix dissolution and consequently expansive remodeling of the vessel. They also contribute to attenuation of fibrous cap and hence susceptibility to rupture. Assessment of metalloproteinase expression and activity should provide information about plaque instability.

1.

Burke A, Farb A, Malcolm GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med 1997;336:1276–82.PubMedCrossRef

2.

Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262–75.PubMed

3.

Lendon CL, Davies MJ, Born GV. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991;87:87–90.PubMedCrossRef

4.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–26.PubMedCrossRef

5.

Narula J, Virmani R, Zaret BL. Radionuclide imaging of atherosclerotic lesions. In: Braunwald E, Dilsizian V, Narula J, editors. Atlas of nuclear cardiology. Philadelphia: Current Medicine; 2003. p. 217–35.

6.

Davies JR, Rudd JH, Weissberg PL, Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol 2006;47:C57–68.PubMedCrossRef

7.

Dunphy MP, Freimann A, Larson SM, Strauss HW. Association of vascular¹⁸F-FDG uptake with vascular calcification. J Nucl Med 2005;46:1278–84.PubMed

8.

Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation. Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825–31.PubMedCrossRef

9.

Tawakol A, Migrino RQ, Bashian GG, Bedris I S, Vermylen D, Cury RC, et al. In vivo ¹⁸F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818–24.PubMedCrossRef

10.

Kietselaer BL, Reutelingsperger CP, Heidendal GA, Mess WH, Hofstra L, Narula J. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350:1472–3.PubMedCrossRef

11.

Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19–31.PubMedCrossRef

12.

Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999;6:41–53.PubMedCrossRef

13.

Fishmann AJ, Rubin RH, Khaw BA, Kramer PB, Wilkinson R, Ahmad M, et al. Radionuclide imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G. J Nucl Med 1989;30:1095–100.

14.

Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 2001;104:203–8.PubMed

15.

Petrov A, Hartung D, Kolodgie F, Narula N, Haider N, Kohut A, et al. Radionuclide imaging inflammation in atherosclerosis by targeting CCR-2 receptors: Would identification of vulnerable plaques become feasible? J Nucl Cardiology 2003;10(1):S37.

16.

Sadeghi MM, Schechner JS, Krassilnikova S, Gharanei AA, Zhang J, Kirkiles-Smith N, et al. Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. Transplant Proc 2004;36:1585–91.PubMedCrossRef

17.

Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1–31.PubMedCrossRef

18.

Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207–14.PubMedCrossRef

19.

Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324–33.PubMed

20.

Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614–24.PubMedCrossRef

21.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: structure, function and biochemistry. Circ Res 2003;92:827–39.PubMedCrossRef

22.

Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503–9.PubMed

23.

Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899–904.PubMedCrossRef

24.

Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–503.PubMedCrossRef

25.

Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human atherosclerosis. Implication for plaque rupture. Arterioscler Thromb Vasc Biol 1996;16:1070–3.PubMed

26.

Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, et al. Matrilysin is expressed by lipid-laden macrophages at sides of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748–53.PubMedCrossRef

27.

Hannson GK, Jonasson L, Lojstehd B, Kocher O. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 1988;72:135–41.CrossRef

28.

Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368–72.PubMedCrossRef

29.

Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579–85.PubMedCrossRef

30.

Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodeling. J Vasc Res 2003;40:329–43.PubMedCrossRef

31.

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 2002;90:251–62.PubMed

32.

Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209–15.PubMedCrossRef

33.

Pearce E, Tregouet DA, Samnegard A, Morgan AR, Cox C, Hamsten A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 2005;97:1070–6.PubMedCrossRef

34.

Johnson JL, Frietsche-Danielson R, Behrendt M, Westin-Eriksson A, Wennbo H, Herslof M, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 2006;71:586–95.PubMedCrossRef

35.

Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733–8.PubMedCrossRef

36.

Kolodgie F, Edwards S, Petrov A, Sachleben R, Hartung D, Weber DK, et al. Noninvasive detection of matrix metalloproteinase upregulation in experimental atherosclerotic lesions and its abrogation by dietary modification. Circulation 2001;104:II694.

37.

Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157–67.PubMedCrossRef

38.

Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1994;14:840–56.

39.

Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1992;12:120–34.PubMed

40.

Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15:1512–31.PubMed

41.

Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998;97:2433–44.PubMed

42.

Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002;22:1452–8.PubMedCrossRef

43.

Luan Z, Chase AL, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769–75.PubMedCrossRef

44.

Kopka K, Breyholz HJ, Wagner S, Law MP, Riemann B, Schroer S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol 2004;31:257–67.PubMedCrossRef

45.

Schäfers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schäfers KP, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109:2554–9.PubMedCrossRef

46.

Deguchi J, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55–62.PubMedCrossRef

47.

Gupta S, Reutelingsperger C, Narula J. Mortals turn me on... J Nucl Med 2005;46:906–8.PubMed

Title: Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions
Authors: Dagmar Hartung
Michael Schäfers
Shinichiro Fujimoto
Bodo Levkau
Navneet Narula
Klaus Kopka
Renu Virmani
Chris Reutelingsperger
Leo Hofstra
Frank D. Kolodgie
Artiom Petrov
Jagat Narula
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0435-0

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties